SG Americas Securities LLC Makes New Investment in uniQure (NASDAQ:QURE)

SG Americas Securities LLC acquired a new position in shares of uniQure (NASDAQ:QURE) during the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 17,159 shares of the biotechnology company’s stock, valued at approximately $116,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. BlackRock Inc. raised its position in uniQure by 0.5% in the second quarter. BlackRock Inc. now owns 4,944,977 shares of the biotechnology company’s stock valued at $56,669,000 after purchasing an additional 24,805 shares during the period. State Street Corp raised its position in uniQure by 29.5% in the third quarter. State Street Corp now owns 3,063,265 shares of the biotechnology company’s stock valued at $57,467,000 after purchasing an additional 698,121 shares during the period. Morgan Stanley raised its position in uniQure by 111.6% in the third quarter. Morgan Stanley now owns 2,681,409 shares of the biotechnology company’s stock valued at $17,992,000 after purchasing an additional 1,413,959 shares during the period. 683 Capital Management LLC raised its position in uniQure by 21.6% in the third quarter. 683 Capital Management LLC now owns 1,575,000 shares of the biotechnology company’s stock valued at $10,568,000 after purchasing an additional 280,000 shares during the period. Finally, Vanguard Group Inc. raised its position in uniQure by 10.9% in the third quarter. Vanguard Group Inc. now owns 1,434,004 shares of the biotechnology company’s stock valued at $26,903,000 after purchasing an additional 141,382 shares during the period. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Analyst Ratings Changes

QURE has been the topic of a number of research analyst reports. HC Wainwright reduced their target price on uniQure from $30.00 to $25.00 and set a “buy” rating on the stock in a research report on Friday, March 1st. Royal Bank of Canada reiterated an “outperform” rating and issued a $28.00 price objective on shares of uniQure in a report on Tuesday, January 16th. Mizuho cut their price objective on uniQure from $10.00 to $7.00 and set a “neutral” rating on the stock in a report on Monday, March 4th. The Goldman Sachs Group downgraded uniQure from a “buy” rating to a “neutral” rating and cut their price objective for the company from $63.00 to $8.00 in a report on Thursday, February 29th. Finally, StockNews.com upgraded uniQure to a “sell” rating in a report on Friday, March 1st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $32.00.

uniQure Price Performance

Shares of NASDAQ QURE opened at $4.71 on Friday. The stock’s 50-day moving average is $5.39 and its two-hundred day moving average is $6.06. The company has a debt-to-equity ratio of 0.49, a current ratio of 8.85 and a quick ratio of 8.68. uniQure has a 1-year low of $4.61 and a 1-year high of $22.48. The company has a market cap of $225.33 million, a price-to-earnings ratio of -0.73 and a beta of 0.95.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported ($1.53) earnings per share for the quarter, topping the consensus estimate of ($1.54) by $0.01. uniQure had a negative return on equity of 99.31% and a negative net margin of 1,947.09%. The company had revenue of $6.69 million for the quarter, compared to the consensus estimate of $3.20 million. Analysts forecast that uniQure will post -4.49 EPS for the current fiscal year.

Insider Transactions at uniQure

In other news, COO Pierre Caloz sold 9,455 shares of the company’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $6.47, for a total transaction of $61,173.85. Following the completion of the transaction, the chief operating officer now directly owns 85,643 shares of the company’s stock, valued at approximately $554,110.21. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, CFO Christian Klemt sold 15,906 shares of the stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $6.38, for a total transaction of $101,480.28. Following the completion of the transaction, the chief financial officer now directly owns 116,948 shares of the company’s stock, valued at approximately $746,128.24. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO Pierre Caloz sold 9,455 shares of the stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $6.47, for a total value of $61,173.85. Following the transaction, the chief operating officer now directly owns 85,643 shares of the company’s stock, valued at $554,110.21. The disclosure for this sale can be found here. In the last ninety days, insiders sold 53,265 shares of company stock valued at $339,845. 4.05% of the stock is currently owned by corporate insiders.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.